At this time, benign brain tumor and cerebrovascular disease research are underfunded and the public remains unaware of the magnitude of this disease.

Nearly 80,000 Americans will be diagnosed with a brain tumor this year. They join more than 700,000 Americans who are currently living with the fear, frustration and uncertainty a brain tumor diagnosis brings. Approximately 68% of these tumors are benign (non-cancerous), while 32% are malignant. All types of brain tumors can be deadly, even benign brain tumors, if they interfere with portions of the brain responsible for vital bodily functions. Brain tumors do not discriminate, inflicting men, women, and children of all races and ethnicities.

American Brain Tumor Association

 

Dr. Edward Smith, Director of Pediatric Cerebrovascular Neurosurgery at Boston Children’s Hospital, wrote the following explanation of the importance of research on benign tumors and vascular disease:

Neurosurgery has a distinct clinical need for improved diagnostic tools to detect cerebrovascular disease and brain tumors. In some cases, particularly stroke-causing conditions, symptoms do not appear until it is too late. Neurosurgeons seek to better define disease prognosis so that they can provide the most effective treatments and follow-up care. Laboratory research and its resulting discoveries help us develop tools that translate into improved patient care.

 

While much focus is often applied to malignant cancers, there remains a profound need to address research on other neurosurgical diseases, such as benign tumors and vascular disease. Many benign brain tumors are (thankfully) no longer immediately fatal, but the lifetime burden of living with disease – including repeated scans, multiple surgeries, hospitalizations and neurological deficits – means that families face huge costs (both psychological and financial) in the long-term management of tumors.

Similar to benign brain tumors, the pediatric neurovascular lesions (like arteriovenous malformations (AVMs) and cavernous malformations (CCMS)) unfortunately confer massive financial and medical burdens to affected families. AVMs can cause death every time that they bleed. Cavernous malformations often rebleed throughout life – unpredictably – devastating patients and families over years and years.

Published data suggest that the financial burden to each patient with these diseases averages at $4 million dollars per year (Stroke. 2009 Jun;40(6):1973-9). The chronic medical, financial and psychological burdens associated with these disorders means that there is an immediate, underserved need to focus research on these conditions.